1 / 14

Liquid Biopsy Market to be US$ 3.4 Billion by 2024

Access Full Research: <br><br>https://www.renub.com/liquid-biopsy-market-p.php<br><br>As per Renub Research analysis Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies.<br><br>Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.<br>

renubresearch
Download Presentation

Liquid Biopsy Market to be US$ 3.4 Billion by 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category: Diagnostics Market Report

  2. Liquid Biopsy Market Analyst View: • Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024. • GetFree Customization in this Report • Research Report Title: • Liquid Biopsy Market, Global Analysis by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen)

  3. Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024. Access Full Research: https://www.renub.com/liquid-biopsy-market-p.php Get Free Customization in this Report As per Renub Research analysis Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024, witnessing the worldwide increasing prevalence of cancer and raising awareness regarding the minimal invasive liquid biopsy technology across the world. Today, liquid biopsy has paved the road of cancer diagnosis and treatment by offering a complete treatment response in real time without the need of serial traditional (solid-tissue) biopsies. Today, the population across the globe is growing and aging and so is the global burden of cancer; it is estimated that by the year 2030, the global cancer burden will reach nearly 21.7 Million new cancer cases and be around 13 Million cancer deaths. It is also expected that the low and middle income countries accounts for 60% of the cancer deaths due to the lack of medical resources and proper healthcare systems.

  4. Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024. Request a free sample copy of the report:https://www.renub.com/contactus.php The cases of cancer increases very rapidly around the world owing to the adoption of unhealthy lifestyles and behaviors such as smoking, poor diet, physical inactivity etc. These rising cases of cancer will drive the liquid biopsy market to thrive in the coming years. As liquid biopsy is a simple and non-invasive technique it enables physicians to discover a range of information about patient’s tumor and provide clues about the treatment that a patient’s needs. Renub Research report titled “Liquid Biopsy Market, by Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others), Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes), Sample (Plasma/Serum, Urine & Others), Clinical Application (Monitoring, Prognosis, Theranostics & Screening), Regions (North America, Europe, Asia-Pacific, Latin America and Middle East/Africa), Companies (Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics Inc., Genomic Health, NeoGenomics Laboratories, Qiagen)” provides a complete analysis of Global Liquid Biopsy Market.

  5. Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024.

  6. Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024. By Cancer – Lung Cancer Controls the Liquid Biopsy Market The report studies the market of the following cancer segments: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer & Others. Lung cancer and Breast cancer together accounts for the considerable market share in the global liquid biopsy market. By Product – Majority of Liquid Biopsy Market held by Kits & Consumables The report studies the market of the following product segments: Kits & consumables, Instruments and Services. More than 90% of liquid biopsy market is comprised by kits & Consumables and Instruments. By Circulating Biomarkers The report studies the liquid biopsy market by Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA) & Exosomes. Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) together holds significant market share By Sample – Plasma/Serum accounts for the maximum market In terms of Sample used for liquid biopsy, the global liquid biopsy market has been studied as Plasma/Serum, Urine and Others.

  7. Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024. By Region – North America &Europe will drive the Liquid Biopsy Market North America and Europe together controls the Liquid Biopsy Market. In addition; the report also provides the complete geographical analysis of Asia-Pacific, Latin America and Middle East/Africa Liquid Biopsy Market. Companies Analysis Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept Inc., Biocartis, Myriad Genetics, Inc., Genomic Health, NeoGenomics Laboratories, Qiagen; which has been studied thoroughly in the report. Client can Purchase this Report in Sections from below link: Access full Research: https://www.renub.com/liquid-biopsy-market-p.php All the 9 Companies Studied in Report have been Studied from 3 Points •    Company Overview    •    Product Portfolio•    Financial Insight

  8. Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024. This market research report provides a complete analysis of the Liquid Biopsy Market, Growth Drivers, Challenges, and their projections for the upcoming years. By Cancer •    Lung Cancer •    Breast Cancer •    Colorectal Cancer•    Prostate Cancer •    Others   By Product •    Kits & Consumables •    Instruments•    Services By Circulating Biomarkers •    Circulating Tumor Cells (CTCs) •    Circulating Tumor DNA (ctDNA)•    Exosomes By Sample •    Plasma/Serum •Urine •Others

  9. Liquid Biopsy Market is projected to exceed US$ 3.4 Billion by the year 2024. By Clinical Application •    Monitoring •    Prognosis•    Theranostics •    Screening By Regions •    North America •    Europe•    Asia-Pacific  •    Latin America•    Middle East/Africa By Companies •    Thermo Fisher Scientific Inc. •    Roche Diagnostics•    Bio-Rad Laboratories Inc. •Biocept Inc.•    Biocartis •    Myriad Genetics, Inc.•    Genomic Health •NeoGenomics Laboratories•    Qiagen

  10. Table of Contents for Liquid Biopsy Market Key Topics Covered 1.    Executive Summary 2.    Global - Liquid Biopsy Market 3.    Market Share – Global Liquid Biopsy 3.1    By Region 3.2    By Cancer3.3    By Product 3.4    By Circulating Biomarkers 4.    Region - Liquid Biopsy Market 4.1    North America 4.2    Europe4.3    Asia-Pacific 4.4    Latin America4.5    Middle East & Africa 5.    Cancer - Liquid Biopsy Market 5.1    Lung Cancer 5.2    Breast Cancer5.3    Colorectal Cancer 5.4    Prostate Cancer5.5    Others

  11. Table of Contents for Liquid Biopsy Market 6.    By Product - Liquid Biopsy Market 6.1    Kits & Consumables 6.2    Instruments6.3    Services 7.    Circulating Biomarkers - Liquid Biopsy Market 7.1    Circulating Tumor Cells (CTCs) 7.2    Circulating Tumor DNA (ctDNA)7.3    Exosomes 8.    By Clinical Application - Liquid Biopsy Market 8.1    Monitoring 8.2    Prognosis8.3    Theranostics 8.4    Screening 9.    By Sample - Liquid Biopsy Market 9.1    Plasma / Serum 9.2    Urine9.3    Others 10.    Thermo Fisher Scientific Inc – Company Analysis 10.1    Product Portfolio

  12. Table of Contents for Liquid Biopsy Market 11    Roche Diagnostics – Company Analysis 11.1    Product Portfolio 12.    Bio-Rad Laboratories Inc – Company Analysis 12.1    Product Portfolio 13.    Biocept, Inc. – Company Analysis 13.1    Product Portfolio 13.2    Financial Insight 14.    Biocartis – Company Analysis 14.1    Product Portfolio 14.2    Financial Insight 15.    Myriad Genetics, Inc – Company Analysis 15.1    Product Portfolio 15.2    Financial Insight 16.    Genomic Health – Company Analysis 16.1    Product Portfolio 16.2    Financial Insight 17.    NeoGenomics Laboratories – Company Analysis 17.1    Product Portfolio 17.2    Financial Insight

  13. Table of Contents for Liquid Biopsy Market 18.    Qiagen – Company Analysis 18.1    Product Portfolio18.2    Financial Insight 19.    Growth Drivers 19.1    Real-Time Evaluation, Convenient and Accuracy19.2    Increasing Demand for Minimally-Invasive Biopsy Techniques19.3    Technical Advancement & Personalized Therapies 20.    Challenges 20.1    Barriers for Liquid Biopsies20.2    High Cost with Uncertain or Limited Reimbursement for Liquid Biopsy

  14. GetFree Customization in this Report • Diagnostics Market Reports: • https://www.renub.com/diagnostics-14-c.php

More Related